A promising outlook of the Cirrhosis market owing to the anticipated launch of emerging drugs by the key companies during the forecast period (2021-30)
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
A promising outlook of the Cirrhosis market owing to the anticipated launch of emerging drugs by the key companies during the forecast period (2021-30)
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal Cancers
January 8, 2021 GMT
PETACH TIKVA, Israel (BUSINESS WIRE) Jan 8, 2021
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced a scientific paper titled, “Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial” was published in the peer reviewed journal
ADVERTISEMENT
The paper highlights and analyzes results from Can-Fite’s Phase II study, a randomized placebo-controlled trial to investigate Namodenoson as a 2nd-line treatment for advanced hepatocellular carcinoma (HCC) and moderate hepatic dysfunction, as defined by Child–Pugh B (CPB) scores of 7–9. Even thoug